Compare Johnson & Johnson (JNJ) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Johnson & Johnson trades at $249.21 (market cap $598.96B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.67. The key difference: Johnson & Johnson pays a 2.15% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | XDTE | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Income / Options Overlay |
52-Week High | $267.24 | $44.76 |
52-Week Low | $164.36 | $36.00 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
XDTE (Roundhill S&P 500 0DTE Covered Call Strategy ETF) trades at $38.44, down 0.1% with a bearish technical signal. The ETF generates income through daily options strategies but faces concerns about net asset value erosion despite high dividend yields. Recent news highlights the fund's 32% yield but questions its sustainability as the math may not hold up over time.
The outlook remains cautious due to structural risks in the covered call strategy potentially limiting upside during market rallies. While offering frequent distributions, investors face the risk of underperforming the underlying S&P 500 index during strong bull markets. The fund's viability depends on market volatility conditions favorable to options selling strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
